Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with anti-TNF (REDES-TNF): Study protocol for a randomized controlled trial

Caridad Pontes, Jordi Gratacós, Ferran Torres, Cristina Avendaño, Jesús Sanz, Antoni Vallano, Xavier Juanola, Eugenio Miguel, Raimon Sanmartí, Gonzalo Calvo

Research output: Contribution to journalArticleResearchpeer-review

5 Citations (Scopus)

Abstract

© 2015 Pontes et al. Background: Dose reduction schedules of tumor necrosis factor antagonists (anti-TNF) as maintenance therapy in patients with spondyloarthritis are used empirically in clinical practice, despite the lack of clinical trials providing evidence for this practice. Methods/Design: To address this issue the Spanish Society of Rheumatology (SER) and Spanish Society of Clinical Pharmacology (SEFC) designed a 3-year multicenter, randomized, open-label, controlled clinical trial (2 years for inclusion and 1 year of follow-up). The study is expected to include 190 patients with axial spondyloarthritis on stable maintenance treatment (≥4 months) with any anti-TNF agent at doses recommended in the summary of product characteristics. Patients will be randomized to either a dose reduction arm or maintenance of the dosing regimen as per the official labelling recommendations. Randomization will be stratified according to the anti-TNF agent received before study inclusion. Patient follow-up, visit schedule, and examinations will be maintained as per normal clinical practice recommendations according to SER guidelines. The study aims to test the hypothesis of noninferiority of the dose reduction strategy compared with standard treatment. The first patients were recruited in July 2012, and study completion is scheduled for the end of April 2015. Discussion: The REDES-TNF study is a pragmatic clinical trial that aims to provide evidence to support a medical decision now made empirically. The study results may help inform clinical decisions relevant to both patients and healthcare decision makers.
Original languageEnglish
Article number370
JournalTrials
Volume16
Issue number1
DOIs
Publication statusPublished - 20 Aug 2015

Keywords

  • DMARDs (biologic)
  • Disease Activity
  • Spondyloarthritis/therapy
  • Treatment

Fingerprint Dive into the research topics of 'Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with anti-TNF (REDES-TNF): Study protocol for a randomized controlled trial'. Together they form a unique fingerprint.

Cite this